A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
Drugs used to protect against ionizing radiation. They are usually of interest for use in radiation therapy but have been considered for other, e.g. military, purposes.
Decreased salivary flow.
Harmful effects of non-experimental exposure to ionizing or non-ionizing radiation in VERTEBRATES.
Experimentally produced harmful effects of ionizing or non-ionizing RADIATION in CHORDATA animals.
The process by which chemical compounds provide protection to cells against harmful agents.
Pathological processes of the TESTIS.
Production of a radiographic image of a small or very thin object on fine-grained photographic film under conditions which permit subsequent microscopic examination or enlargement of the radiograph at linear magnifications of up to several hundred and with a resolution approaching the resolving power of the photographic emulsion (about 1000 lines per millimeter).
INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.
Samarium. An element of the rare earth family of metals. It has the atomic symbol Sm, atomic number 62, and atomic weight 150.36. The oxide is used in the control rods of some nuclear reactors.
Those persons legally qualified by education and training to engage in the practice of pharmacy.
Total pharmaceutical services provided to the public through community pharmacies.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
Tumors or cancer of the LUNG.
Prudent standard preventive measures to be taken by professional and other health personnel in contact with persons afflicted with a communicable disease, to avoid contracting the disease by contagion or infection. Precautions are especially applicable in the diagnosis and care of AIDS patients.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
The services rendered by members of the health profession and non-professionals under their supervision.
The practice of replacing one prescribed drug with another that is expected to have the same clinical or psychological effect.
Hospital department responsible for the receiving, storing, and distribution of pharmaceutical supplies.
Abuse, overuse, or misuse of a substance by its injection into a vein.
Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585)
Errors in prescribing, dispensing, or administering medication with the result that the patient fails to receive the correct drug or the indicated proper drug dosage.
A medical specialty concerned with maintaining health and providing medical care to children from birth to adolescence.
Institutions specializing in the care of cancer patients.
Voluntary cooperation of the patient in taking drugs or medicine as prescribed. This includes timing, dosage, and frequency.
Use of written, printed, or graphic materials upon or accompanying a product or its container or wrapper. It includes purpose, effect, description, directions, hazards, warnings, and other relevant information.
The action of a drug that may affect the activity, metabolism, or toxicity of another drug.
Available manpower, facilities, revenue, equipment, and supplies to produce requisite health care and services.
A component of the PUBLIC HEALTH SERVICE that provides leadership related to the delivery of health services and the requirements for and distribution of health resources, including manpower training.
Individual's rights to obtain and use information collected or generated by others.
A publication issued at stated, more or less regular, intervals.
A quantitative measure of the frequency on average with which articles in a journal have been cited in a given period of time.
"The business or profession of the commercial production and issuance of literature" (Webster's 3d). It includes the publisher, publication processes, editing and editors. Production may be by conventional printing methods or by electronic publishing.
The evaluation by experts of the quality and pertinence of research or research proposals of other experts in the same field. Peer review is used by editors in deciding which submissions warrant publication, by granting agencies to determine which proposals should be funded, and by academic institutions in tenure decisions.
A mitochondrial myopathy characterized by slowly progressive paralysis of the levator palpebrae, orbicularis oculi, and extraocular muscles. Ragged-red fibers and atrophy are found on muscle biopsy. Familial and sporadic forms may occur. Disease onset is usually in the first or second decade of life, and the illness slowly progresses until usually all ocular motility is lost. (From Adams et al., Principles of Neurology, 6th ed, p1422)
The clear, viscous fluid secreted by the SALIVARY GLANDS and mucous glands of the mouth. It contains MUCINS, water, organic salts, and ptylin.
Persons who have experienced a prolonged survival after serious disease or who continue to live with a usually life-threatening condition as well as family members, significant others, or individuals surviving traumatic life events.
Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.
Articles on conferences sponsored by NIH presenting summary statements representing the majority agreement of physicians, scientists, and other professionals convening for the purpose of reaching a consensus on a subject of interest. This heading is used for NIH consensus conferences as a means of scientific communication. In indexing it is viewed as a type of review article and as a tag for any article appearing in any publication of the NIH Office of Medical Applications of Research (OMAR).
A province of eastern Canada, one of the Maritime Provinces with NEW BRUNSWICK; PRINCE EDWARD ISLAND; and sometimes NEWFOUNDLAND AND LABRADOR. Its capital is Halifax. The territory was granted in 1621 by James I to the Scotsman Sir William Alexander and was called Nova Scotia, the Latin for New Scotland. The territory had earlier belonged to the French, under the name of Acadia. (From Webster's New Geographical Dictionary, 1988, p871 & Room, Brewer's Dictionary of Names, 1992, p384)
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)

Evaluation of uroprotective efficacy of amifostine against cyclophosphamide induced hemorrhagic cystitis. (1/192)

The role of amifostine in the prevention of cyclophosphamide-induced hemorrhagic cystitis (HC) was evaluated in the rat model. Urinary bladders from control rats that received no drugs (group I) were compared with those from rats receiving cyclophosphamide alone at a dose of 150 mg/kg (group II), and two other groups receiving amifostine at 100 mg/kg (group III) and 200 mg/kg (group IV), 15 min prior to cyclophosphamide. Bladders were assessed macroscopically and histologically at 24 h and after 7 days. All the animals that received cyclophosphamide alone developed severe HC. On the basis of the scores of macroscopic and histologic changes, animals that received amifostine showed excellent uroprotection. Only 2/6 rats in group III and 1/6 rats in group IV developed mild HC at 24 h. None of the rats in either of these groups showed any evidence of HC at 7 days. It is concluded that amifostine protects the urothelium against cyclophosphamide-induced HC.  (+info)

The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects. (2/192)

Radio- and chemotherapy for the treatment of malignancies are often associated with significant toxicity. One approach to reduce the toxicity is the concomitant treatment with chemoprotective agents. This article reviews two sulfhydryl compounds, namely the agent WR-2721 (amifostine), a compound recently registered for use in human in many countries, and the natural occurring compound glutathione (GSH). GSH is not registered as a chemoprotective agent. WR-2721 is an aminothiol prodrug and has to be converted to the active compound WR-1065 by membrane-bound alkaline phosphatase. WR-1065 and GSH both act as naturally occurring thiols. No protective effect on the tumour has been found when these compounds are administered intravenously. There is even in vitro evidence for an increased anti-tumour effect with mafosfamide after pretreatment with WR-2721, and in vivo after treatment with carboplatin and paclitaxel. Randomized clinical studies have shown that WR-2721 and GSH decrease cisplatin-induced nephrotoxicity and that WR-2721 reduces radiation radiotherapy-induced toxicity. Side-effects associated with WR-2721 are nausea, vomiting and hypotension, GSH has no side-effects. An exact role of WR-2721 and GSH as chemoprotectors is not yet completely clear. Future studies should examine the protective effect of these drugs on mucositis, cardiac toxicity, neuro- and ototoxicity, the development of secondary neoplasms and their effect on quality of life.  (+info)

Direct amifostine effect on renal tubule cells in rats. (3/192)

Clinical trials indicate that amifostine offers protection against cisplatin-induced nephrotoxicity. It is unclear whether a direct pharmacological t on renal tubular cells is involved. We investigated the effect of amifostine pretreatment on the tubular apparatus and evaluated its nephroprotective potential. A total of 32 rats were treated by i.p. administration of 0.9% saline solution (group 1), 5 mg/kg cisplatin (group 2), 25 mg/kg amifostine (group 3), and 25 mg/kg amifostine followed by 5 mg/kg cisplatin (group 4) after 30 min. We recorded elevation of N-acetyl-beta-D-glucosaminidase (NAG) in 24 h pooled urine as a specific marker for tubular lesions, renal leakage of magnesium as an unspecific nephrotoxicity marker, and survival over a 10-day observation period. A significant (P < 0.002) increase in urinary NAG after treatment was documented only in cisplatin-treated group 2 [day 2 (mean+/-SE), 93+/-2.1 units/gram creatinine; day 4, 70.6+/-16 units/gram creatinine; normalization at day 8]. Treatment with amifostine before cisplatin administration resulted in a slight urinary NAG leakage (day 2, 2.8+/-1.8 units/gram creatinine; day 4, 13.8+/-13 units/gram creatinine; normalization at day 6). No increase in urinary enzyme levels was seen in the other groups, and there were no significant differences in urinary magnesium between all groups. Four of eight rats in the cisplatin-treated group and one of eight rats in the amifostine plus cisplatin-treated group died.  (+info)

Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group. (4/192)

BACKGROUND: Cisplatin is one of the most active cytotoxic agents available for the treatment of patients with head and neck cancer. In a previous phase II study with weekly administration of cisplatin, a response rate of 51% was achieved. However, only in a minority of the patients the planned high dose intensity of 80 mg/m2/week could be reached because of toxicity, mainly thrombocytopenia and ototoxicity. Amifostine is a cytoprotective drug that can diminish the toxicity of alkylating agents and platinum compounds. Therefore the effect of amifostine on toxicity and activity of weekly cisplatin was investigated in a randomized study. PATIENTS AND METHODS: Patients with locally advanced, recurrent or metastatic head and neck cancer were eligible. Patients were randomized to weekly cisplatin 70 mg/m2 for six cycles preceded by amifostine 740 mg/m2, or cisplatin only. Cisplatin was administered in hypertonic saline (3% NaCl) as a one-hour infusion; amifostine was administered as a 15-minute infusion directly before the administration of cisplatin. RESULTS: Seventy-four patients were entered in the study. The median number of cisplatin administrations was 6 (range 2-6), equal in both arms. In both treatment arms the median dose intensity of cisplatin achieved was the planned 70 mg/m2/week. In the cisplatin only arm 6 out of 206 cycles were complicated by thrombocytopenia grade 3 or 4 versus 1 of 184 cycles in the amifostine arm (P = 0.035). Hypomagnesaemia grade 2 + 3 was significantly less observed in the amifostine arm (P = 0.04). Neurotoxicity analyzed by serial vibration perception thresholds (VPT) showed a diminished incidence of subclinical neurotoxicity in the amifostine arm (P = 0.03). No protective effect on renal and ototoxicity could be shown. Hypotension was the main side effect of amifostine but only of relevance in one patient. The antitumor activity of cisplatin was preserved as 63% of the evaluable patients in the amifostine arm responded compared to 50% of the evaluable patients in the cisplatin alone arm. CONCLUSION: Our study indicated that in combination with weekly administered cisplatin amifostine reduced the risk of thrombocytopenia, hypomagnesemia as well as subclinical neurotoxicity, but did not result in a higher dose intensity of cisplatin. Addition of amifostine did not compromise the antitumor effect of cisplatin.  (+info)

Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. (5/192)

PURPOSE: To determine whether the neurotoxicity of paclitaxel 250 mg/m(2) given over 3 hours every 3 weeks could be reduced by pretreatment with amifostine 910 mg/m(2). Secondary objectives included comparing myelosuppression, myalgias, and response rates of the two groups. PATIENTS AND METHODS: Forty women with metastatic breast cancer were randomized to receive either paclitaxel alone (arm 1) or paclitaxel preceded by amifostine (arm 2). All were assessable for toxicity, and 37 were assessable for response. At baseline and after each cycle, all patients completed questionnaires for neurologic symptoms and had standardized neurologic examinations, including objective assessments of power and vibration sense. In addition, standard follow-up assessments for other toxicities and tumor response were undertaken. Changes from baseline after courses 1, 2, and 3 were assessed. The sample size was sufficient to detect a 50% improvement in the expected determination in sensory change. RESULTS: There were no differences observed in any of the measures of neurotoxicity. Other toxicity was similar in arms 1 and 2, including hair loss (95% v 90%), neurosensory changes (100% v 100%), fatigue/lethargy (85% v 90%), myalgia (95% v 90%), and grade 4 neutropenia (47% v 60%). Nausea, vomiting, dizziness, hypotension, and sneezing were more common in the amifostine arm. Response rates (22.2% v 36.8%) and paclitaxel pharmacokinetics were not significantly different. CONCLUSION: There was no protection from paclitaxel-related neurotoxicity or hematologic toxicity in this study. These results suggest that the mechanism of action of paclitaxel-related toxic effects is not amenable to the cytoprotective action of amifostine.  (+info)

American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. (6/192)

PURPOSE: Because toxicities associated with chemotherapy and radiotherapy can adversely affect short- and long-term patient quality of life, can limit the dose and duration of treatment, and may be life-threatening, specific agents designed to ameliorate or eliminate certain chemotherapy and radiotherapy toxicities have been developed. Variability in interpretation of the available data pertaining to the efficacy of the three United States Food and Drug Administration-approved agents that have potential chemotherapy- and radiotherapy-protectant activity-dexrazoxane, mesna, and amifostine-and questions about the role of these protectant agents in cancer care led to concern about the appropriate use of these agents. The American Society of Clinical Oncology sought to establish evidence-based, clinical practice guidelines for the use of dexrazoxane, mesna, and amifostine in patients who are not enrolled on clinical treatment trials. METHODS: A multidisciplinary Expert Panel reviewed the clinical data regarding the activity of dexrazoxane, mesna, and amifostine. A computerized literature search was performed using MEDLINE. In addition to reports collected by individual Panel members, all articles published in the English-speaking literature from June 1997 through December 1998 were collected for review by the Panel chairpersons, and appropriate articles were distributed to the entire Panel for review. Guidelines for use, levels of evidence, and grades of recommendation were reviewed and approved by the Panel. Outcomes considered in evaluating the benefit of a chemotherapy- or radiotherapy-protectant agent included amelioration of short- and long-term chemotherapy- or radiotherapy-related toxicities, risk of tumor protection by the agent, toxicity of the protectant agent itself, quality of life, and economic impact. To the extent that these data were available, the Panel placed the greatest value on lesser toxicity that did not carry a concomitant risk of tumor protection. RESULTS AND CONCLUSION: Mesna: (1) Mesna, dosed as detailed in these guidelines, is recommended to decrease the incidence of standard-dose ifosfamide-associated urothelial toxicity. (2) There is insufficient evidence on which to base a guideline for the use of mesna to prevent urothelial toxicity with ifosfamide doses that exceed 2.5 g/m(2)/d. (3) Either mesna or forced saline diuresis is recommended to decrease the incidence of urothelial toxicity associated with high-dose cyclophosphamide use in the stem-cell transplantation setting. Dexrazoxane: (1) The use of dexrazoxane is not routinely recommended for patients with metastatic breast cancer who receive initial doxorubicin-based chemotherapy. (2) The use of dexrazoxane may be considered for patients with metastatic breast cancer who have received a cumulative dosage of 300 mg/m(2) or greater of doxorubicin in the metastatic setting and who may benefit from continued doxorubicin-containing therapy. (3) The use of dexrazoxane in the adjuvant setting is not recommended outside of a clinical trial. (4) The use of dexrazoxane can be considered in adult patients who have received more than 300 mg/m(2) of doxorubicin-based therapy for tumors other than breast cancer, although caution should be used in settings in which doxorubicin-based therapy has been shown to improve survival because of concerns of tumor protection by dexrazoxane. (5) There is insufficient evidence to make a guideline for the use of dexrazoxane in the treatment of pediatric malignancies, with epirubicin-based regimens, or with high-dose anthracycline-containing regimens. Similarly, there is insufficient evidence on which to base a guideline for the use of dexrazoxane in patients with cardiac risk factors or underlying cardiac disease. (6) Patients receiving dexrazoxane should continue to be monitored for cardiac toxicity. Amifostine: (1) Amifostine may be considered for the reduction of nephrotoxicity in patients receiving cisplatin-based chemoth  (+info)

The potential of amifostine: from cytoprotectant to therapeutic agent. (7/192)

BACKGROUND AND OBJECTIVE: Amifostine is an inorganic thiophosphate cytoprotective agent known chemically as ethanethiol, 2-[(3-aminopropyl)amino]dihydrogen phosphate. It is a pro-drug of free thiol that may act as a scavenger of free radicals generated in tissues exposed to cytotoxic drugs, and binds to reactive metabolites of such drugs. Amifostine was originally developed as a radioprotective agent in a classified nuclear warfare project. Following declassification of the project it was evaluated as a cytoprotective agent against toxicity of the alkylating drugs and cisplatin. In fact, pretreatment with amifostine was well tolerated and reduced the cumulative hematologic, renal and neurological toxicity associated with cisplatin, cyclophosphamide and vinblastine therapy of advanced and metastatic solid tumors. The objective of this review is to focus the importance of amifostine as a myeloprotective and cytoprotective drug during treatment with chemotherapeutics, presenting the most recent results, and to discuss the application of amifostine in the therapy of myelodysplastic syndromes. EVIDENCE AND INFORMATION SOURCES: The material analyzed in this study includes data published or under publication by the authors as full papers or clinical protocols. Articles and abstracts published in Journals covered by Medline constitute the other source of information. STATE OF THE ART AND PERSPECTIVES: Amifostine, formerly known as WR-2721, is an organic thiophosphate that was developed to protect normal tissues selectively against the toxicities of chemotherapy and radiation. Amifostine is a pro-drug that is dephosphorylated at the tissue site to its active metabolite by alkaline phosphatase. Differences in the alkaline phosphatase concentrations of normal versus tumor tissues can result in greater conversion of amifostine in normal tissues. Once inside the cell the free thiol provides an alternative target to DNA and RNA for the reactive molecules of alkylating or platinum agents and acts as a potent scavenger of the oxygen free radicals induced by ionizing radiation and some chemotherapies. Preclinical animal studies demonstrated that the administration of amifostine protected against a variety of chemotherapy-related toxicities including cisplatin-induced nephrotoxicity, cisplatin-induced neurotoxicity, cyclophosphamide- and bleomycin-induced pulmonary toxicity, and the cytotoxicities (including cardiotoxicity) induced by doxorubicin and related chemotherapeutic agents. Amifostine was shown to protect a variety of animal species from lethal doses of radiation. Studies in tumor-bearing animals demonstrated that the administration of amifostine results in cytoprotection without loss of antitumor activity. Multiple phase I studies were carried out with amifostine in combination with chemotherapy for various neoplasms. Appropriate doses of amifostine resulted to be 740-910 mg/m(2) in a single dose regimen, and 340 mg/m(2) in a multiple dose regimen. Amifostine afforded not only hematologic protection, but also other organ protection from cytotoxic agents such as nephrotoxicity, mucositis and peripheral neuropathy from cisplatin. Many studies have been performed to investigate cytoprotective efficacy of amifostine. In brief, amifostine gives hematologic protection from cyclophosphamide, carboplatin, mitomycin C, fotemustine and radiotherapy; renal and peripheral nerve protection from cisplatin; mucosa, skin, and salivary gland from radiotherapy. In phase I/II studies these properties have been confirmed, together with a generally good tolerability of the drug, hypotension being the most common side effect. It has been observed that amifostine possibly enhances the anti-tumor effect of carboplatin, nitrogen mustard, melphalan, and cisplatin combined with 5-FU or vinblastine. For all these characteristics, amifostine is at present broadly used as supportive treatment during chemotherapy, in lymphomas and solid tumors, and its spec  (+info)

Amifostine inhibits hematopoietic progenitor cell apoptosis by activating NF-kappaB/Rel transcription factors. (8/192)

We investigated the involvement of NF-kappaB/Rel transcription factors that reportedly can inhibit apoptosis in various cell types in the antiapoptotic mechanism of the cytoprotectant amifostine. In the nontumorigenic murine myeloid progenitor 32D cells incubated with amifostine, we detected a reduction of the IkappaBalpha cytoplasmic levels by Western blotting and a raising of nuclear NF-kappaB/Rel complexes by electrophoretic mobility shift assay. Amifostine inhibited by more than 30% the growth factor deprivation-induced apoptosis, whereas its effect failed when we blocked the NF-kappaB/Rel activity with an NF-kappaB/Rel-binding phosphorothioate decoy oligodeoxynucleotide. In human cord blood CD34(+) cells, the NF-kappaB/Rel p65 subunit was detectable (using immunofluorescence analysis) mainly in the cytoplasm in the absence of amifostine, whereas its presence was appreciable in the nuclei of cells incubated with the cytoprotectant. In 4 CD34(+) samples incubated for 3 days in cytokine-deficient conditions, cell apoptosis was reduced by more than 30% in the presence of amifostine (or amifostine plus a control oligo); the effect of amifostine was abolished in cultures with the decoy oligo. These findings indicate that the inhibition of hematopoietic progenitor cell apoptosis by amifostine requires the induction of NF-kappaB/Rel factors and that the latter can therefore exert an antiapoptotic activity in the hematopoietic progenitor cell compartment. Furthermore, the identification of this specific mechanism underlying the survival-promoting activity of amifostine lends support to the possible use of this agent in apoptosis-related pathologies, such as myelodysplasias.  (+info)

TY - JOUR. T1 - In vivo effects of IL-4, IL-10, and amifostine on cytokine production in patients with acute myelogenous leukemia. AU - Tao, M.. AU - Li, Biaoru. AU - Nayini, J.. AU - Sivaraman, S.. AU - Song, S.. AU - Larson, A.. AU - Toofanfard, M.. AU - Chen, H.. AU - Venugopal, P.. AU - Preisler, H. D.. N1 - Funding Information: This work was supported by the National Cancer Institute Grand 1-PO-01C A 7560641.. PY - 2001. Y1 - 2001. N2 - Both IL-4 and IL-10 have been shown in vitro to inhibit leukemia cell secretion of IL-1β, GM-CSF, and TNFα, and increase leukemia cell release of IL-1ra. In this study, we have investigated the in vivo effects of IL-4, IL-10, and amifostine on cytokine production in patients with acute myelogenous leukemia (AML). Serum IL-1ra, IL-1β, TNFα, GM-CSF, and SCF levels were measured in AML patients who received IL-4, IL-10, or amifostine. No significant changes in the serum levels of IL-1ra, IL-1β, TNFα, GM-CSF, and SCF were found in AML patients who received ...
This is the first randomized explanatory study that assessed amifostine efficacy in patients undergoing external beam irradiation for pelvic malignancies by means of combining clinical, endoscopic and histological data.. Patients on prophylactic subcutaneous amifostine developed less acute RC compared to patients who did not receive amifostine prophylaxis, yet the small size of this study did not allow us to reach to statistically significant findings. However, acute RC and grade IV radiation colitis did not occur in the amifostine arm but only in four patients (17.4%) who did not receive amifostine prophylaxis (arm R). In parallel with our data a study with one hundred patients with inoperable, unresectable, or recurrent adenocarcinoma of the rectum were stratified and randomized to amifostine plus radiation therapy (A) or radiation therapy (R) only treatment arms. According to this study, the administration of amifostine concomitant to radiation for advanced rectal cancer, was reported to ...
It evaluated the impact of amifostine on reducing GI toxicities among multiple myeloma patients undergoing transplant.. Amifostine is used to reduce the side effects of certain chemotherapy agents and radiation treatment. It is known as a cytoprotective agent, protecting the body from some of the potentially serious side effects of treatment. One hundred and seven patients participated in this study. Amifostine 740?mg was administered at 24?hours and 15?min before high-dose melphalan. The study concluded that amifostine therapy decreased GI toxicity without any significant adverse effects while preserving the anti-myeloma efficacy of high-dose melphalan and auto-HTC. About Ethyol® (amifostine). Ethyol is indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer. It is indicated to reduce the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck ...
TY - JOUR. T1 - Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors. T2 - A Childrens Oncology Group study. AU - Marina, Neyssa. AU - Chang, Kay W.. AU - Malogolowkin, Marcio. AU - London, Wendy B.. AU - Frazier, A. Lindsay. AU - Womer, Richard B.. AU - Rescorla, Frederick. AU - Billmire, Deborah F.. AU - Davis, Mary M.. AU - Perlman, Elizabeth J.. AU - Giller, Roger. AU - Lauer, Stephen J.. AU - Olson, Thomas A.. PY - 2005/8/15. Y1 - 2005/8/15. N2 - BACKGROUND. High-dose cisplatin combined with etoposide and bleomycin (HD-PEB) improves event-free survival (EFS) in advanced pediatric germ-cell tumors (PGCT), but has significant ototoxicity. Amifostine appears to protect against toxicity. The authors combined amifostine with HDPEB and evaluated the efficacy and toxicity, specifically whether ototoxicity deccreased. METHODS. Eligibility criteria included age , 15 years and unresectable Stage III/IV ...
OBJECTIVES: I. Evaluate whether the addition of the radioprotector amifostine can reduce the incidence and severity of non-hematologic toxicity, specifically esophagitis and pneumonitis, during concurrent hyperfractionated radiotherapy and chemotherapy (with paclitaxel and carboplatin) in patients with stage II, IIIA, or IIIB non-small cell lung cancer. II. Evaluate the differences in quality of life and symptom distress, specifically dysphagia, between patients receiving amifostine and those not receiving amifostine. III. Evaluate the relationship of tobacco use and alcohol use during treatment to appraisals of quality of life and symptom distress, specifically esophagitis, in the two groups. IV. Evaluate the efficacy of induction therapy with paclitaxel and carboplatin followed by concurrent chemotherapy and hyperfractionated radiotherapy in these patients.. OUTLINE: This is an open-label treatment and randomized supportive care study. Patients are stratified according to disease stage (II vs ...
Amifostine protects normal tissue from the cytotoxic damage induced by radiation and chemotherapy. in this study. 39 consecutive newly diagnosed children with osteosarcoma were assessed; 20 received amifostine and 19 did not. the chemotherapy regimen included an induction phase of three cycles of cisplatin (100 mg/m(2)), carboplatin (500 mg/m(2)), and doxorubicin (60 mg/m(2)), followed by surgery. Alternating cycles of cisplatin/ifosfamide (9 mg/m(2)), ifosfamide/doxorubicin. carboplatin/doxorubicin, and ifosfamide/carboplatin were administered every 3 weeks to complete 26 weeks of treatment. Amifostine was administered 15 minutes before the infusions of cisplatin and carboplatin in a total of 193 infusions. Side effects during infusions and renal, hearing, and bone marrow toxicities were evaluated and compared between the two groups. Hypotension was observed in 28 (14.5%) infusions. No patient required discontinuation of therapy. Fewer than two episodes of vomiting occurred in 130 (71%) ...
RATIONALE: Nasopharyngeal carcinoma is a kind of malignant tumor which is treated primarily by radiation therapy. This therapeutic strategy often causes adverse effects such as dysfunction of salivary gland and lesion of oral mucosa. With concurrent chemotherapy, it may also cause toxicity to kidney, bone marrow, and other organs or tissues. When administered prior to chemoradiotherapy, Amifostine has been proved to has the ability of protecting the normal from these adverse effects so as to improve the patient tolerance. However, there are also some side effects of Amifostine itself, such as nausea, vomiting and hypotension, especially when high dose is applied.. PURPOSE: This phase II randomized controlled trial is to study the protecting effect and its safety of Amifostine every-other-day regimen compared with standard everyday regimen on adverse effects such as myelosuppression, xerostomia and mucositis, in patients with nasopharyngeal carcinoma Stage T1-T4, N0-N3, M0 and undergoing ...
Ethyol (Amifostine) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related medications including drug comparison and health resources.
Dry mouth occurs very often in patients who receive radiation treatment. Amifostine is a drug approved to reduce the short and long-term occurrence of
I started the injections, but doc stopped them when my reactions (rashes) worsened. My doc said that normally half his patients were able to do injections the entire time. This round, there were 5 of us starting, and I was the last to have to quit, so I guess you never know. Another doc I spoke with said they never recommended Amifostine, as there was no conclusive trials showing efficacy, and we couldnt be certain that it wouldnt help to preserve cancer cells. My injection nurse said you could normally tell who got the injections, because they did better with saliva later. 5 months out of treatment, I have some saliva (dunno what percentage of normal). I have to drink water whenever I eat, and get dry mouth from time to time. I have more saliva now than I did when treatment ended. ...
Amifostine Hydrate was originally developed by the military as a radioprotectant during the event of a nuclear attack. It is basically a prodrug that is dephosphorylated in the tissues by alkaline phosphatase into a free thiol metabolite which is critical in reducing the toxic effects of chemo and radiation therapy on healthy cells.. According to the European Society for Medical Oncology (ESMO), head and neck cancer has a global incidence rate of 3.9 and 2.3% per 100,000 people worldwide. Xerostomia is an adverse event associated with radiation therapy which is recommended in patients suffering from head and neck cancer. The recommended dose for xerostomia treatment is 200 mg/m2 once every day as a 3-minute infusion usually 15 minutes before radiation therapy. Nephrotoxicity or cumulative renal toxicity is associated with patients receiving cisplatin chemotherapy. The recommended dose for nephrotoxicity treatment is 910 mg/m2 once every day as a 15 minutes infusion, it needs to be given 30 ...
This phase III trial is studying how well radiation therapy, amifostine, and chemotherapy work in treating young patients with newly diagnosed nasophary
This study is investigating whether the addition of another drug, Amifostine, can reduce the side effects of current combination treatment (radiation and
Detailed Amifostine dosage information for adults. Includes dosages for Non-Small Cell Lung Cancer, Malignant Disease and Ovarian Cancer; plus renal, liver and dialysis adjustments.
Learn about the known and possible side effects of Amifostine Not everyone will experience one or all of these side effects. In case of any doubt please consult your doctor or pharmacist
Current drugs shortage notification for Amifostine Injection including reason for shortage, estimated resupply dates, and alternative drug therapy if available.
Fingerprint Dive into the research topics of Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: A Childrens Oncology Group study. Together they form a unique fingerprint. ...
This phase III trial is studying how well radiation therapy, amifostine, and chemotherapy work in treating young patients with newly diagnosed nasopharyngeal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs, such as amifostine, may protect normal cells from the side effects of radiation therapy. Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with amifostine and chemotherapy may kill more tumor cells. Stanford is currently not accepting patients for this trial.. ...
Although previous studies have found that doses of amifostine between 740-910 mg/m2 are effective, this study suggested that lower doses may be effective and increase tolerability. The study suggested that 20% of the usual dose of amifostine is capable of offering adequate protection against diarrhea and mucositis associated with 5-FU. Although the 500 mg/m2 and 800 mg/m2 dose levels were equally effective in decreasing the risk of all grades of diarrhea, the lower dose was better tolerated. The 150 dose level was the best tolerated and was nearly as effective as higher doses in preventing severe and grade 1 diarrhea. Amifostine appears to offer protection against gastrointestinal adverse effects and permit higher doses of 5-FU. ...
Oxidative Medicine and Cellular Longevity is a unique peer-reviewed, Open Access journal that publishes original research and review articles dealing with the cellular and molecular mechanisms of oxidative stress in the nervous system and related organ systems in relation to aging, immune function, vascular biology, metabolism, cellular survival and cellular longevity. Oxidative stress impacts almost all acute and chronic progressive disorders and on a cellular basis is intimately linked to aging, cardiovascular disease, cancer, immune function, metabolism and neurodegeneration. The journal fills a significant void in todays scientific literature and serves as an international forum for the scientific community worldwide to translate pioneering
OncoLink, the Webs first cancer resource,provides comprehensive information on coping with cancer, cancer treatments, cancer research advances, continuing medical education, cancer prevention, and clinical trials
This information from Lexicomp® explains what you need to know about this medication, including what its used for, how to take it, its side effects, and when to call your healthcare provider.
1. Persistent rotavirus vaccine shedding in a new case of severe combined immunodeficiency: A reason to screen. Uygungil B, Bleesing JJ, Risma KA, McNeal MM, Rothenberg ME. JACI 2009; 125(1): 270-271.. 2. Identifying an at-risk population of children with recurrent near-fatal asthma exacerbations: Carroll CL, Uygungil B, Zucker AR, Schramm CM. J Asthma. 2010 May; 47(4):460-4.. 3. A novel subset of CD4+ TH2 memory/effector cells that produce inflammatory IL-17 cytokine and promote the exacerbation of chronic allergic asthma. Wang YH, Voo KS, Liu B, Chen CY, Uygungil B, Spoede W, Bernstein JA, Huston DP, Liu YJ. J Exp Med. 2010 207(11): 2479-91. PMCID: PMC2964570. 4. Immunodeficiency: a problem with the faucet or the drain? Uygungil, B., Assaad, A, Khurahana Hershey, GK, Risma K. Ann Allergy Asthma Immunol. 2011 107(6):547-9. 5. Severe allergic reaction to thiol-based cytoprotective agents mesna and amifostine in a child with ...
The 14 reports in this special supplement discuss the use of the cytoprotectant amifostine in patients with cancer of the head and neck, esophagus, lung, and cervix, as well as those with lymphoma and acute myelogenous leukemia. Discussions focus on the potential of this agent to both reduce radiation side effects such as xerostomia and permit dose escalation of chemotherapy and/or radiotherapy. Improvements in treatment outcome and quality of life as a result of cytoprotection are examined. 1
Exporter of Pharmaceutical Injections - Adriamycin Injection, Adenocarcinoma Injection, Amifostine Injections and Fulvenat Injection offered by Medicare Remedies Private Limited, Navi Mumbai, Maharashtra.
Compounds having the formula: are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, ...
3-(2,4-bis(4-((5-(4,6-bis(2-aminopropylamino)-1,3,5-triazin-2-ylamino)-4-hydroxy-2,7-disulfonaphthalen-3-yl)azo)phenylamino)-1,3,5-triazin-6-ylamino)propyldiethylammonium lactate ...
Looking for online definition of Ethyol in the Medical Dictionary? Ethyol explanation free. What is Ethyol? Meaning of Ethyol medical term. What does Ethyol mean?
Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation - Article Information
Global Amifostine Market Data Survey Report 2025 is a market research report available at US $1500 for a Single User PDF License from RnR Market Research Reports Library.
Mechanism of Action Prodrug; pharmacologically active free thiol metabolite can reduce the toxic effects of cisplatin (is available to bind to , and detoxify, reactive metabolites of cisplatin). It can also act as a scavenger of free radicals that may be generated in tissues exposed to cisplatin. It also protects against cell damage from radiation and other alkylators. Other mechanisms may be responsible for protection against paclitaxel toxicity and for therapeutic effect in MDS.. ...
Some important lessons in designing and conducting clinical trials of radiation protectors and/or mitigators were learned from RTOG 9801, a 243-patient prospective, randomized trial of the radioprotector amifostine, aiming to reduce esophagitis in the setting of lung cancer treated with radiochemotherapy (44). Accrual was slow initially, partly due to concern among some clinicians about the potential for tumor protection seen in some animal studies (45). Ultimately, RTOG 9801 did meet its accrual goal and showed no difference in tumor control or overall survival between the 2 arms. Concerns about protecting tumor may be less in the case of mitigators, which are administered after the course of radiation therapy has been completed.. Another challenge was correctly interpreting the results because RTOG 9801 showed the disconnect that can occur between endpoints measured by clinicians versus patients (46). According to its primary endpoint (NCI-CTCAE grade of esophagitis, determined by ...
RBB 001, a recombinant fusion protein, is a targeted cytoprotectant in development with Rubicon Biotechnology for the treatment of myocardial or cerebral
TY - JOUR. T1 - Effect of the radioprotector WR2721 on irradiation-induced injury to ciliated cells of eustachian tube. AU - Jung, Timothy T.K.. AU - Park, Young Min. AU - Panossian, David. AU - Weeks, Douglas. AU - Miller, Stanley K.. AU - Sandefur, Jere. AU - Krohn, Kenneth A.. PY - 1992/5. Y1 - 1992/5. N2 - Our previous studies revealed that injury to the ciliated cells of the eustachian tube may be the primary cause of irradiation-induced serous otitis media. The purpose of this study was to investigate the effects of the radioprotector WR2721 on irradiation-induced injury to ciliated cells of the eustachian tube (ET) in chinchillas. Twelve chinchillas were divided into two groups: the control group and the experimental group, which was pretreated with a single intraperitoneal dose of the radioprotector S-2-[3-aminopropylamino]ethylphosphorothioic acid (WR2721) 400 mg/kg. The two groups were exposed to 30 Gy of 13-MeV electrons in a single fraction to the area of the bullae and nasopharynx. ...
Most ionizing radiation-induced damage is caused by radical oxygen species (ROS). Some radioprotectors, such as amifostine, exert radioprotective effects by scavenging radical oxygen species. Recent studies show that hydrogen (H) has antioxidant activities that protect the brain and intestine agains …
Marty - Youre right...on the time difference. Like you, the bigger doses during the nine weeks took anywhere from 6 - 8+ hours with all of the additional solutions and only one chemo at a time.. The Carboplatin usually only took an hour or so. The day I had chemo, Id also go down and do the rads after.. Well, Id get the Amifostine injection in the tummy first, then rads. Amifostine injection and rads every day for seven weeks....uggg.. Pat - about the only side effect I did have during the Cisplatin, Taxotere and 5FU was I lost my hair (all hair) around week 3 - 4, then it starting growing back within a few weeks.. When I started the Carboplatin, the hair was already back, though really fine an just like first hair...LOL, it was kind of humorous.. Well, thinking back, I did also lose all of my toe nails (a little weird) my finger nails became really brittle also. I also initially had hiccups frequently, and my potassium dropped, had to have extra for 10 days once.. JG ...
CMG}} __NOTOC__ ==Drug interactions with Amlodipine== ===Major Interactions=== {{refbegin,3}} * [[tizanidine]] * [[Zanaflex]] {{refend}} ===Moderate Interactions=== {{refbegin,3}} * [[A-Hydrocort]] * [[A-Methapred]] * [[ABC Plus Senior]] * [[ABC to Z]] * [[Abilify]] * [[Abilify Discmelt]] * [[acebutolol]] * [[Acetocot]] * [[Acetylsalicylic Acid]] * [[ACTH]] * [[ACTH Gel]] * [[ACTH-40 HP]] * [[ACTH-80]] * [[Acthar]] * [[Acthar Gel H.P.]] * [[Acthrel]] * [[Actiq]] * [[Actron]] * [[Acuprin 81]] * [[Adbeon]] * [[ADEKs]] * [[Adlone-40]] * [[Adlone-80]] * [[Adrenocot]] * [[Adrenocot L.A.]] * [[Advil]] * [[Advil Childrens]] * [[Advil Junior Strength]] * [[Advil Liquigel]] * [[Advil Migraine]] * [[Advil Pediatric]] * [[Aflaxen]] * [[Agenerase]] * [[Akbeta]] * [[aldesleukin]] * [[Aleve]] * [[Aleve Caplet]] * [[Aleve Easy Open Arthritis]] * [[Aleve Gelcap]] * [[Alfenta]] * [[alfentanil]] * [[Alka-Mints]] * [[Alkets]] * [[Alkums]] * [[Ami-Natal Plus One Improved]] * [[amifostine]] * [[Amigesic]] * ...
In this study, the cell lines HeLa, 3T3-Swiss albino, CHO-Kl, and ARPE-19 were cultured and co-incubated with variable concentrations of S-phosphorylated thiols and Nacetylcysteine. Using MTT assays, the cultures were ...
1. Put the steaks in a large bowl with the onion, garlic and chilli powder; season. Pour over the wine, ensuring the meat is covered. Cover with cling film and chill for at least 4 hours, preferably overnight.. 2. For the anchovy butter, beat the anchovies, garlic and butter until smooth, creamy and fawn-coloured, then season to taste.. 3. To cook the steaks, discard the marinade and pat the steaks completely dry on kitchen paper. Season, coat with the oil and cook on a hot barbecue (or griddle pan) for about 4-6 minutes, turning regularly, until cooked to your liking. Rest under a sheet of foil while you toast the bread.. 4. Spread the toast with anchovy butter and slice the steaks to serve alongside.. ...
The exact meaning of the medical terminology,Amifostine - A drug used as a chemoprotective drug to control some of the side effects of chemotherapy and radiation therapy, is clearly explained in Medindia s glossary of medical terms
Support Care Cancer. 2013 Jan;21(1):357-64. doi: 10.1007/s00520-012-1613-6. Epub 2012 Oct 3. Consensus Development Conference; Research Support, Non-U.S. Govt; Review
ConsumerLab.com reviews radioprotective Iodine pills in response to terrorist threats - Quality of products is high, but local access is poor
C60 protects against radiation-induced cell damage. The 2010 publication Dendro[C(60)]fullerene DF-1 provides radioprotection to radiosensitive mammalian cells reports: In this study, the ability of the C(60) fullerene derivative DF-1 to protect radiosensitive cells from the effects of high doses of gamma irradiation was examined. Earlier reports of DF-1s lack of toxicity in these cells were confirmed, and DF-1 was also observed to protect both human lymphocytes and rat intestinal crypt cells against radiation-induced cell death. We determined that DF-1 protected both cell types against radiation-induced DNA damage, as measured by inhibition of micronucleus formation. DF-1 also reduced the levels of reactive oxygen species in the crypt cells, a unique capability of fullerenes because of their enhanced reactivity toward electron-rich species. The ability of DF-1 to protect against the cytotoxic effects of radiation was comparable to that of amifostine, another ROS-scavenging radioprotector. ...
Radikal Therapeutics (RTX) is developing a novel cytoprotective agent (R-801) for the prevention of ischemia-reperfusion injury (IRI) following lung transplanta...
Sucralfate belongs to the class of medications called gastroduodenal cytoprotective agents. Sucralfate is used to treat duodenal and stomach ulcers and to prevent duodenal ulcers. The liquid form of sucralfate is also used to prevent bleeding due to stress ulcers in people who are critically ill. It works by forming a coating over the ulcer. This coating protects the ulcer from stomach acid, allowing it to heal.
Apple pectin is a great radioprotective agent. In one study, the pectin was so effective, it reduced the caesium-137 load by up to 62 percent in one month.
/PRNewswire/ --Pinnacle Biologics is pleased to announce the appointment of Bioprojet Pharma, effective March 15, 2012, as its exclusive distributor for ETHYOL...
Airmar 117WR-4 Transducer Housing Wrench. Part Number:117WR-4. UPC: Price:$29.95 USD.117WR-4 Transducer Housing WrenchA single-handed wrench that holds the main thru-hull housing via the wrench flats on the side of the housing to facilitate tightening of the hull nu
In Drosophila and other animals, the body plan is predetermined in the egg. Trudi Schupbach explains that the signaling molecule Gurken is key to axes formation.
Aim of Study: Propolis is a resinous bee product, rich of polyphenolic compounds and flavonoids. It is known that in different geographic zones its chemical composition varies due to the different plant sources. Many biological properties including antimicrobial, antioxidative, anti-inflammatory, antitumoral, antigenotoxic, antimutagenic, cytostatic activities have been ascribed to propolis. These biological effects are predominantly attributed to its content of polyphenols. In this study, we aimed to evaluate the radioprotective effect of ethanolic extract of Turkish propolis. (EETP) against -ray-induced DNA damage on fibroblast cells using comet assay for the first time. Materials and Methods: Fibroblast cells were pretreated 15 and 30 min with concentrations of 100, 200 and 300 g/mL EETP then they were exposed to 3 Gy -rays. Amifostine (synthetic aminothiol compound) was used as a positive control. Results: The results showed a significant decrease in -ray-induced DNA damage on cells treated ...
Nigella sativa oil is a promising natural radioprotective agent against immunosuppressive and oxidative effects of ionizing radiation.
When should a patient s constitutional type (a as android, g as gynoid, and n responses (see chapter 9 ). The organization of the frontal subcortical circuits, the mesocorticolimbic dopaminergic, and other small bowel follow-through: An examination, with barium studies of patients with murdered propecia hematological disorders may be due to a lymphocytic or plasma exchange of nutrients by rats or mice vaccinated with ultraviolet-attenuated cercariae have been mixed. A low-fat diet or supplement of antioxidants, cytoprotective agents, and hypovolemia should be like uid sliding on the levels of compartmental organization. In this case, ct with 3d reconstruction ca 15-7 triphasic with delayed-phase ct. The disease is established when rh (d) antibodies are positive in aml treatment regimens have activity against osteoarthritis. The inset shows the frontal lobes. This sometimes means that it will soon be undertaken. Are there other treatments and are sensitive to the neocortex of anxious patients ...
N-(Aryl)-2-arylethenesulfonamides and pharmaceutically acceptable salts and compositions thereof are useful as antiproliferative agents, including, for example, anticancer agents. They are also useful as radioprotective agents.
... is a class of prescription drugs in India appearing as an appendix to the Drugs and Cosmetics Rules, 1945 introduced in 1945. These are drugs which cannot be purchased over the counter without the prescription of a qualified doctor.The manufacture and sale of all drugs are covered under the Drugs and Cosmetics Act and Rules. It is revised at times based on the advice of the Drugs Technical Advisory Board, part of the Central Drugs Standard Control Organization[1] in the Ministry of Health and Family Welfare. The most recent schedule H (2006) lists 536 drugs from abacavir to zuclopenthixol.[2] However, enforcement of Schedule H laws in India is lax, compared to the more restrictive Schedule X, for which a mandatory documentation trail must be maintained.[3] ...
amifostine 'WR2721' the first selective-target and broad-spectrum radioprotector, upregulates DNA repair. Filgrastim ('Neupogen ... N-acetyl cysteine protects against DNA damage, suggested to be comparable to amifostine. 5-Androstenediol ABC294640 an in ... "Amifostine: The First Selective-Target and Broad-Spectrum Radioprotector". The Oncologist. 12 (6): 738-47. doi:10.1634/ ...
Amifostine protects the gums and salivary glands from the effects of radiation.[citation needed] Photodynamic therapy may have ... While not specifically a chemotherapy, amifostine is often administered intravenously by a chemotherapy clinic prior to IMRT ...
Amifostine, which is used in cancer chemotherapy. Chlorpyrifos, a popular insecticide. Malathion, a popular insecticide. ...
... that there is some low-quality evidence to suggest that amifostine prevents the feeling of dry mouth or reduce the risk of ...
Examples include: Amifostine, approved by the FDA in 1995, which helps prevent kidney damage in patients undergoing cisplatin ... "Chemoprotective Agents: Amifostine, Mesna, Dexrazoxane - What is Chemotherapy? - Chemocare". chemocare.com. Retrieved 2016-10- ... "Common Side Effects of Ethyol (Amifostine) Drug Center". RxList. Retrieved 2019-03-25. Chemoprotective entry in the public ...
Amifostine has been studied in an effort to prevent problems. Nephrotoxicity is a dose-limiting side effect. Neurotoxicity ( ...
Bjelogrlic SK, Radic J, Radulovic S, Jokanovic M, Jovic V (December 2007). "Effects of dexrazoxane and amifostine on evolution ...
Some drugs (amifostine, N-acetylcysteine) containing thiol groups may protect from such harmful alkylation. 2-alkenal reductase ...
The terminology is used loosely and thiophosphates include P-S single bonds as illustrated by the drug amifostine. P-S single ... Selected organothiophosphates Echothiophate used for treatment of glaucoma Amifostine, which is used in cancer chemotherapy ...
Kuna, Pavel (2004). "Acute toxicity and radioprotective effects of amifostine (WR-2721) or cystamine in single whole body ...
... of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine ...
Examples of drugs that would be classified as Type II DMFs include Amifostine, Caffeine, Desonide Micro, Ibuprofen Softgels, ...
Administration of amifostine has been used in attempts to prevent cisplatin-induced ototoxicity, but the American Society of ...
Another systematic review showed, that there is some low-quality evidence to suggest that amifostine prevents the feeling of ...
... was more effective at protecting from ionizing radiation-induced gastrointestinal epithelial apoptosis than amifostine (the ...
Acetyl-L-carnitine All-trans retinoic acid Amifostine Amitriptyline Calcium magnesium Cannabinoids Diethyldithiocarbamate ...
... cyclosilicate V03AF01 Mesna V03AF02 Dexrazoxane V03AF03 Calcium folinate V03AF04 Calcium levofolinate V03AF05 Amifostine ...
... amifostine - amikacin - aminocamptothecin - aminoglutethimide - aminoglycoside antibiotic - aminolevulinic acid - aminopterin ...
... amifostine (INN) Amigesic amiglumide (INN) amikacin (INN) amikhelline (INN) Amikin amilomotide (INN) amiloride (INN) Amin-Aid ...
... amifostine, clofarabine and the latest pralatrexate (approved in 2009). Notable cancer researchers who worked at the institute ...
... is believed to radioprotect normal tissue via Warburg-type effects. Common side effects of amifostine include ... Additional data have shown that amifostine-mediated tumor protection, in any clinical scenario, is unlikely. Amifostine is an ... Contraindications to receiving amifostine include hypersensitivity to amifostine and aminothiol compounds like WR-1065. Ethyol ... Amifostine is also indicated to reduce the incidence of xerostomia in patients undergoing radiotherapy for head and neck cancer ...
... amifostine). Nephrotoxicity is a dose-limiting side effect.[8] ...
... has role antioxidant (CHEBI:22586) amifostine (CHEBI:2636) has role prodrug (CHEBI:50266) amifostine ( ... amifostine (CHEBI:2636) is a diamine (CHEBI:23666) amifostine (CHEBI:2636) is a organic thiophosphate (CHEBI:37512) ... CHEBI:2636 - amifostine. Main. ChEBI Ontology. Automatic Xrefs. Reactions. Pathways. Models. .gridLayoutCellStructure { min- ... amifostine (CHEBI:2636) has functional parent cysteamine (CHEBI:17141) ...
Amifostine Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Before receiving amifostine,. *tell your doctor and pharmacist if you are allergic to amifostine, any other medications, or any ... Amifostine comes as a powder to be mixed with liquid to be injected intravenously (into a vein) by a doctor or nurse in a ... Amifostine may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away: *nausea ...
Amifostine is believed to radioprotect normal tissue via Warburg-type effects. Common side effects of amifostine include ... Additional data have shown that amifostine-mediated tumor protection, in any clinical scenario, is unlikely. Amifostine is an ... Contraindications to receiving amifostine include hypersensitivity to amifostine and aminothiol compounds like WR-1065. Ethyol ... Amifostine is also indicated to reduce the incidence of xerostomia in patients undergoing radiotherapy for head and neck cancer ...
Learn about the known and possible side effects of Amifostine Not everyone will experience one or all of these side effects. In ... Side effect(s) of Amifostine Read the side effects of Amifostine as described in the medical literature. In case of any doubt ... Amifostine - Information. Amifostine is a cytoprotective agent, prescribed for preventing kidney damage due to chemotherapy and ...
Amifostine is used to protect the kidneys from harmful effects caused by cisplatin when given to patients with ovarian cancer. ... Amifostine is also used to prevent severe dry mouth caused by radiation... ... Amifostine is used to help lessen the side effects of certain cancer chemotherapy medications or radiation treatment. ... How is amifostine given?. Amifostine is injected into a vein through an IV. A healthcare provider will give you this injection ...
Detailed Amifostine dosage information for adults. Includes dosages for Non-Small Cell Lung Cancer, Malignant Disease and ... Amifostine should be used with particular care in these and other patients in whom the common amifostine adverse effects of ... If the full dose of amifostine cannot be administered, the dose of amifostine for subsequent chemotherapy cycles should be 740 ... If the full dose of amifostine cannot be administered, the dose of amifostine for subsequent chemotherapy cycles should be 740 ...
Current drugs shortage notification for Amifostine Injection including reason for shortage, estimated resupply dates, and ... Amifostine Injection. Last Updated: December 1, 2016. Status: Resolved. Products Affected - Description * *Amifostine powder ... West-Ward stopped actively marketing amifostine in October 2016. They were the sole supplier of generic amifostine. ...
This study plans to examine the effects of xerostomia when Amifostine is used subcutaneously (by injection). Amifostine has ... Randomized Amifostine For SCCHN. The safety and scientific validity of this study is the responsibility of the study sponsor ... Randomized Amifostine For SCCHN. Official Title ICMJE Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly ... Amifostine is a drug that is used to treat moderate to severe xerostomia (dry mouth) for those who receive radiation therapy ...
Amifostine - Last updated on May 29, 2020. ©2020 Memorial Sloan Kettering Cancer Center. ...
Amifostine) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related medications ... amifostine) for Injection. DESCRIPTION. ETHYOL (amifostine) is an organic thiophosphate cytoprotective agent known chemically ... ETHYOL (amifostine) is indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin ... Amifostine is a white crystalline powder which is freely soluble in water. Its empirical formula is C5H15N2O3PS and it has a ...
Harmonised classification and labelling is a legally binding classification and labelling for a substance, agreed at European Community level. Harmonisation is based on the substances physical, toxicological and eco-toxicological hazard assessment. The Hazard classification and labelling section uses the signal word, pictogram(s) and hazard statements of the substance under the harmonised classification and labelling (CLH) as its primary source of information.. If the substance is covered by more than one CLH entry (e.g. disodium tetraborate EC no. 215-540-4, is covered by three harmonisations: 005-011-00-4; 005-011-01-1 and 005-011-02-9), CLH information cannot be displayed in the InfoCard as the difference between the CLH classifications requires manual interpretation or verification. If a substance is classified under multiple CLH entries, a link to the C&L Inventory is provided to allow users to view CLH information associated with the substance, instead of having the information ...
Amifostine 740 mg was administered at 24 hours and 15 min before high-dose melphalan. The study concluded that amifostine ... Newly Published Data Demonstrates Amifostine Reduces Gastro-Intestinal Toxicity For Multiple Myeloma Patients Amifostine may ... Amifostine is used to reduce the side effects of certain chemotherapy agents and radiation treatment. It is known as a ... About Ethyol® (amifostine). Ethyol is indicated to reduce the cumulative renal toxicity associated with repeated administration ...
Amifostine. ATC Codes. V03AF05 - Amifostine*V03AF - Detoxifying agents for antineoplastic treatment. *V03A - ALL OTHER ... Doxazosin may increase the hypotensive activities of Amifostine.. Approved. Duloxetine. Amifostine may increase the orthostatic ... Riociguat may increase the hypotensive activities of Amifostine.. Approved. Risperidone. Amifostine may increase the ... Amifostine 500 mg vial. 600.0USD vial. DrugBank does not sell nor buy drugs. Pricing information is supplied for informational ...
... Ji Jia,1 Lei Zhang,2 Xiaolei Shi,3 Mingchun Wu,4 ... Ji Jia, Lei Zhang, Xiaolei Shi, et al., "SOD2 Mediates Amifostine-Induced Protection against Glutamate in PC12 Cells," ...
We studied if amifostine could affect the hemodynamic parameters in doxorubicin-pretreated rabbits. The animals were divided ... Amifostine reduces nephrotoxicity and myelotoxicity of alkylating agents. Little is known about its role in preventing ... amifostine iv 30 mg/kg 15 min prior to doxorubicin 2 and 3 mg/kg, respectively, groups 5 and 6--amifostine- and physiological ... Amifostine improves hemodynamic parameters in doxorubicin-pretreated rabbits Pharmacol Rep. Nov-Dec 2006;58(6):966-72. ...
Drug Information available for: Amifostine Amifostine monohydrate Genetic and Rare Diseases Information Center resources: ... Experimental: Amifostine Amifostine IV 2 weeks, followed by 2 weeks rest (4 week cycle) ... Amifostine in Treating Patients With Myelodysplastic Syndrome. The safety and scientific validity of this study is the ... Drug: Amifostine Trihydrate Escalating dose IV for two weeks, followed by 2 weeks of rest. Each treatment cycle is 4 weeks. ...
Amifostine. I took it for about 2 1/2 weeks but it started making me sick and I had to stop. Mine was given by infusion no ... Amifostine. I had a total five shots through a course of 33 rads. After each shot I had nausea and suffered some pretty severe ... Daily Amifostine. I also got the shots each day before my 35 radiation treatments. Each injection was in my stomach. The area ... During my rads treatment I took two shots before they zapped my head called amifostine. I was curious out of the lot of us here ...
Systematic review of amifostine for the management of oral mucositis in cancer patients.. Nicolatou-Galitis O1, Sarri T, Bowen ... Review of the amifostine studies for the prevention and treatment of oral mucositis has found insufficient evidence to support ... The body of evidence for the use of amifostine, in each cancer treatment setting was assigned an evidence level. Based on the ... Thirty papers were reviewed for evidence on amifostine as an intervention for oral mucositis. No guideline was possible for ...
Sinai, New York, evaluated the impact of amifostine on protecting the esophagus. Its aim was to determine if the amifostine ... Cumberland markets branded amifostine in the U.S territory under the name Ethyol® on behalf of Clinigen Group plc who is the ... About Ethyol® (amifostine). Ethyol is indicated to reduce the cumulative renal toxicity associated with repeated administration ... Newly Published Data Demonstrates Amifostine Delayed The Onset Of Acute Esophagitis For Small Cell Lung Cancer Patients. News ...
Blue Cross Blue Shield of Massachusetts is a leading provider of quality health insurance for residents of Massachusetts. Our main goal is to make health care cost-effective by offering health insurance solutions for individuals, families, and large and small businesses at affordable rates.. Our Vision - Making Quality Health Care ...
Amifostine was given daily. In only one case we had to discontinue the amifostine administration. We didnt have any major ... The incidence of fibrosis at 6 months was 28% in amifostine-treated patients vs 53% in patients who did not receive amifostine ... Amifostine significantly reduced esophagitis, reduced late lung toxicity, reduced the clinical symptoms such as dyspnea and ... There were 22 patients in the amifostine group and 23 patients in the control group. This included both non-small-cell lung ...
Although Amifostine has been found to protect lungs from the toxic effects of radiation and bleomycin, its application is ... The current study was undertaken to assess the protective effects of DRDE-30, an analogue of Amifostine, on bleomycin-induced ... The current study was undertaken to assess the protective effects of DRDE-30, an analogue of Amifostine, on bleomycin-induced ... The results demonstrate that the Amifostine analogue, DRDE-30, ameliorates the oxidative injury and lung fibrosis induced by ...
Amifostine cancer drug molecule. Adjuvant drug that protects against cancer chemotherapy side effects. Atoms are represented as ... Keywords: adjuvant, alkaline, amifostin, amifostine, artwork, atomic, cancer, cgi, chemical, chemistry, chemotherapy, ... Caption: Amifostine cancer drug molecule. Adjuvant drug that protects against cancer chemotherapy side effects. Atoms are ...
Amifostine is administered by 10 minute IV infusions.. Irinotecan is administered by IV infusions 15 minutes after completion ... OBJECTIVES: I. Assess the toxicity profile of irinotecan and amifostine when administered. together in patients with metastatic ... of amifostine.. Treatment is repeated every 2 weeks for 6 weeks. This 6 week course is repeated in the. absence of disease ...
Phase I Trial of High Dose Chemotherapy Using Amifostine for In-Vivo Protection of GM-CSF Primed Progenitor Cells. Trial Phase: ... Patients receive intravenous amifostine over 10. minutes on day 0, followed by intravenous cyclophosphamide and carboplatin ... Phase I Trial of High Dose Chemotherapy Using Amifostine for In-Vivo Protection of GM-CSF Primed Progenitor Cells ... Determine the effects of amifostine on the granulocyte and thrombocyte. nadirs produced by this same regimen when administered ...
The unloaded amifostine was also monitored by HPLC to ensure the reaction end point. Amifostine with a retention time of 5.3 ... Preparation of amifostine-loaded CCM (CCM-Ami): CCMAmi was prepared by mixing amifostine trihydrate, PEG-b-PGA, and ferrous ... Figure 5: The ratio of unloaded amifostine in the reaction solution over time. Three percent of amifostine was determined after ... PGA and amifostine. The reaction was stirred at room temperature for 24 hours. To remove the unreacted amifostine and ferrous ...
Amifostine. Description. Amifostine is only found in individuals that have used or taken this drug. It is a phosphorothioate ... Showing metabocard for Amifostine (HMDB0015274). IdentificationTaxonomyOntologyPhysical propertiesSpectraBiological properties ... Orditura M, De Vita F, Roscigno A, Infusino S, Auriemma A, Iodice P, Ciaramella F, Abbate G, Catalano G: Amifostine: A ... Buschini A, Anceschi E, Carlo-Stella C, Regazzi E, Rizzoli V, Poli P, Rossi C: Amifostine (WR-2721) selective protection ...
Vial of 500mg Amifostine for reconstitution with 9.7mL sterile Saline Injection. May be available on a case-by-case basis ... Vials with 500mg of amifostine for reconstitution. Store at room temperature 20-25oC Preparation:. Reconstitute with 9.7mL of ... then restart Amifostine infusion. SUGGESTED CRITERIA. • Serum calcium levels, especially if symptomatic or at high risk for ...
Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly. A ... versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly. Cancer, 107: 544-553. ... Amifostine (Ethyol) given by rapid IV push is safe and tolerable. Proc Am Soc Clin Oncol. 2001; 20: 300b. ... Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. Int J Radiat Oncol Biol Phys. ...
  • ETHYOL is the trihydrate form of amifostine and is supplied as a sterile lyophilized powder requiring reconstitution for intravenous infusion. (rxlist.com)
  • ETHYOL (amifostine) is indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer. (rxlist.com)
  • ETHYOL (amifostine) for Injection is supplied as a sterile lyophilized powder requiring reconstitution for intravenous infusion. (rxlist.com)
  • ETHYOL® (amifostine) is a prescription drug given by injection prior to each postoperative radiation treatment session for head and neck cancer. (cancer.org)
  • Cumberland markets branded amifostine in the U.S territory under the name Ethyol ® on behalf of Clinigen Group plc who is the market authorization holder and owner of global rights. (prnewswire.com)
  • We undertook a phase III randomized, multicenter trial to investigate whether daily pretreatment with amifostine (Ethyol) could safely reduce the incidence of esophagitis and pneumonitis in patients with lung cancer undergoing definitive conventional radiotherapy. (cancernetwork.com)
  • ETHYOL (amifostine) is a protective medicine. (ethyol.com)
  • Are taking a medicine called amifostine because it contains the same medicine as ETHYOL. (ethyol.com)
  • ETHYOL contains the same medicine as amifostine. (ethyol.com)
  • If you are taking amifostine, do not take ETHYOL. (ethyol.com)
  • Ethyol is the trade name for amifostine. (chemocare.com)
  • In some cases, health care professionals may use the trade name ethyol when referring to the generic drug name amifostine. (chemocare.com)
  • Amifostine (Ethyol) may be considered to decrease the incidence of xerostomia in certain patients undergoing fractionated radiation therapy to the head and neck region. (aafp.org)
  • This week, the Advisor Forum answers a question about the use of amifostine (Ethyol, generic) as a radioprotectant. (oncologynurseadvisor.com)
  • tell your doctor and pharmacist if you are allergic to amifostine, any other medications, or any of the ingredients in amifostine injection. (medlineplus.gov)
  • Your doctor will tell you to stop taking your blood pressure medicine 24 hours before you receive amifostine injection. (medlineplus.gov)
  • This study plans to examine the effects of xerostomia when Amifostine is used subcutaneously (by injection). (clinicaltrials.gov)
  • Vial of 500mg Amifostine for reconstitution with 9.7mL sterile Saline Injection. (cancercare.ns.ca)
  • There are several advantages offered by SbQ amifostine over IV amifostine including easier administration and a favorable window between drug injection and radiation delivery. (oncolink.org)
  • We are among the distinguished suppliers, exporters, and wholesalers of Amifostine Injection in the industry. (oncologydrugs.co.in)
  • Constantly increasing inpatient admission of patients suffering from cancer and Availability of Amifostine Hydrate injection at a low cost in the government-funded hospitals and clinics determine its market growth. (curiousdesk.com)
  • Amifostine was originally indicated to reduce the cumulative renal toxicity from cisplatin in non-small cell lung cancer. (wikipedia.org)
  • a U.S. specialty pharmaceutical company and Clinigen Group plc (AIM: CLIN, 'Clinigen') , the global pharmaceutical and services company, announce a new publication in Leukemia & Lymphoma , with study results showing that amifostine decreases gastro-intestinal (GI) toxicity in patients who receive treatment for their multiple myeloma. (prnewswire.com)
  • The study concluded that amifostine therapy decreased GI toxicity without any significant adverse effects while preserving the anti-myeloma efficacy of high-dose melphalan and auto-HTC. (prnewswire.com)
  • Amifostine is an organic thiophosphate cytoprotective agent indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer or non-small cell lung cancer and also to reduce the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer. (drugbank.ca)
  • Amifostine is a prodrug that is dephosphorylated by alkaline phosphatase in tissues to a pharmacologically active free thiol metabolite, believed to be responsible for the reduction of the cumulative renal toxicity of cisplatin and for the reduction of the toxic effects of radiation on normal oral tissues. (drugbank.ca)
  • Acute pulmonary toxicity was also significantly lower in the patients treated with amifostine. (cancernetwork.com)
  • Amifostine significantly reduced esophagitis, reduced late lung toxicity, reduced the clinical symptoms such as dyspnea and cough, and reduced the incidence of pneumonitis and fibrosis. (cancernetwork.com)
  • Although Amifostine has been found to protect lungs from the toxic effects of radiation and BLM, its application is limited due to associated toxicity and unfavorable route of administration. (frontiersin.org)
  • OBJECTIVES: I. Assess the toxicity profile of irinotecan and amifostine when administered together in patients with metastatic colorectal cancer. (knowcancer.com)
  • I. To estimate the response and efficacy of amifostine (amifostine trihydrate) in reducing the toxicity associated with platinum agents. (clinicaltrials.gov)
  • To estimate the efficacy of amifostine in reducing the toxicity associated with cisplatinum in children with resected tumors receiving treatment 01 by randomizing to receive or not receive amifostine. (clinicaltrials.gov)
  • This trial tested the hypothesis that SbQ amifostine was associated with an improved toxicity profile with regards to late xerostomia versus IV amifostine. (oncolink.org)
  • In this preliminary analysis of GORTEC 2000-2002, the toxicity profiles of subcutaneous and intravenous amifostine appeared relatively similar. (oncolink.org)
  • Amifostine induced a G1 arrest and protected against paclitaxel toxicity in p53-proficient but not in p53-deficient cells. (nih.gov)
  • OBJECTIVES: - Determine the dose-limiting toxicity of amifostine chemoprotection with peripheral blood stem cell transplantation plus chemotherapy in patients with high-risk or relapsed solid tumors or brain tumors. (checkorphan.org)
  • Three well-controlled clinical trials have shown that amifostine can ameliorate cumulative bone marrow toxicity and the acute and chronic neutropenic and/or thrombocytopenic effects of cyclophosphamide. (elsevier.com)
  • Jan. 30, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a U.S. specialty pharmaceutical company and Clinigen Group plc (AIM: CLIN, ' Clinigen ') , the global pharmaceutical and services company, announce a new publication in Leukemia & Lymphoma , with study results showing that amifostine decreases gastro-intestinal (GI) toxicity in patients who receive treatment for their multiple myeloma. (gcs-web.com)
  • This study demonstrated that amifostine has the potential to be a broad spectrum cytoprotectant of normal tissues from toxicity caused by chemotherapy and no effect on therapeutic outcome in lung cancer patients . (bvsalud.org)
  • Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. (bvsalud.org)
  • Amifostine appears to protect against toxicity. (elsevier.com)
  • The authors combined amifostine with HDPEB and evaluated the efficacy and toxicity, specifically whether ototoxicity deccreased. (elsevier.com)
  • Amifostine is a unique drug selectively protecting non-affected tissues from CT-RT induced toxicity. (springer.com)
  • IMSEAR at SEARO: Prophylactic efficacy of combination of DRDE-07 and its analogues with amifostine against sulphur mustard induced systemic toxicity. (who.int)
  • Gautam Anshoo, Gupta Alka, Lomash Vinay, Pant S C, Vijayaraghavan R. Prophylactic efficacy of combination of DRDE-07 and its analogues with amifostine against sulphur mustard induced systemic toxicity. (who.int)
  • Avoid taking blood pressure medication within 24 hours before you receive amifostine. (cigna.com)
  • You may need to drink extra liquids before you receive amifostine. (cigna.com)
  • Patients receive amifostine IV for two weeks, followed by 2 weeks of rest. (clinicaltrials.gov)
  • The remaining 17 patients (group 2) did not receive amifostine. (prnewswire.com)
  • Patients receive amifostine IV over 5 minutes beginning 30 minutes prior to melphalan and thiotepa administration on days -5 to -1. (checkorphan.org)
  • Amifostine is used protect the kidneys from harmful effects of the chemotherapy drug cisplatin in patients that receive this medication for the treatment of ovarian cancer. (medlineplus.gov)
  • When amifostine is used to protect the kidneys against the harmful effects of cisplatin, it is usually given over 15 minutes starting 30 minutes before you receive your chemotherapy treatment. (medlineplus.gov)
  • Amifostine is also sometimes used to prevent and decrease side effects associated with certain chemotherapy medications or radiation treatment and in the treatment of some types of blood cell diseases. (medlineplus.gov)
  • Amifostine (ethiofos) is a cytoprotective adjuvant used in cancer chemotherapy and radiotherapy involving DNA-binding chemotherapeutic agents. (wikipedia.org)
  • Amifostine is a cytoprotective agent, prescribed for preventing kidney damage due to chemotherapy and reducing the mouth dryness due to radiation therapy. (medindia.net)
  • Amifostine is used to help lessen the side effects of certain cancer chemotherapy medications or radiation treatment. (cigna.com)
  • Amifostine will not prevent all side effects of chemotherapy medications. (cigna.com)
  • Amifostine is usually given within 15 to 30 minutes before the start of radiation or chemotherapy. (cigna.com)
  • If the full dose of amifostine cannot be administered, the dose of amifostine for subsequent chemotherapy cycles should be 740 mg/m2. (drugs.com)
  • There are at present only limited data on the effects of amifostine on the efficacy of chemotherapy or radiotherapy in other settings. (rxlist.com)
  • Amifostine is used to reduce the side effects of certain chemotherapy agents and radiation treatment. (prnewswire.com)
  • a U.S. specialty pharmaceutical company and Clinigen Group plc (AIM: CLIN, 'Clinigen') , the global pharmaceutical and services company, announce a new publication in Lung Cancer: Targets and Therapy of a contemporary retrospective series showing that subcutaneous amifostine administered before radiotherapy postponed the onset of acute esophagitis in stage 3 small cell lung cancer patients treated with concomitant doublet chemotherapy and hyperfractionated radiotherapy. (prnewswire.com)
  • A subsequent pilot study involved induction chemotherapy followed by radiotherapy with or without amifostine in patients with advanced lung cancer. (cancernetwork.com)
  • Amifostine significantly reduced acute and late toxicities in chemotherapy-pretreated patients,' Dr. Antonadou said. (cancernetwork.com)
  • Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy. (clinicaltrials.gov)
  • This randomized phase III trial is studying giving combination chemotherapy together with amifostine to see how well it works compared to combination chemotherapy alone in treating patients with liver cancer. (clinicaltrials.gov)
  • Amifostine protects the kidneys during chemotherapy. (rxwiki.com)
  • Amifostine is a prescription medication used to protect the kidneys during chemotherapy and reduces dry mouth during radiation. (rxwiki.com)
  • In these cases, amifostine helps to minimize the harmful side effects of chemotherapy. (chemistrylearner.com)
  • Amifostine is given intravenously almost half an hour before the beginning of radiation therapy or chemotherapy. (chemistrylearner.com)
  • Amifostine is administered with some types of chemotherapy. (chemistrylearner.com)
  • Inside the body, Amifostine is broken down into some other chemicals which act on the harmful constituents of chemotherapy drugs. (chemistrylearner.com)
  • Amifostine a chemoprotectant (KEEM-o-pro-TEK-tant) that can help lessen the side effects of certain cancer chemotherapy medications or radiation treatment. (oncologydrugs.co.in)
  • Despite this clinically significant cytoprotection, amifostine treatment did not adversely affect pathologically proven complete response, overall objective response rates, or survival duration associated with cisplatin/cyclophosphamide chemotherapy. (elsevier.com)
  • Amifostine protects normal tissue from the cytotoxic damage induced by radiation and chemotherapy. (unifesp.br)
  • Aim: Preclinical and clinical evaluation of amifostine (AMI) administration in conjunction with systemic chemotherapy supports its role as a cytoprotective agent of normal tissues without loss or impairing the antitumour effectiveness of chemotherapeutic agents. (hippokratia.gr)
  • Purpose: To determine the role of amifostine as a protectant against cisplatin-induced ototoxicity in patients with average-risk (AR) medulloblastoma treated with craniospinal radiotherapy and four cycles of cisplatin-based, dose-intense chemotherapy and stem-cell rescue. (elsevier.com)
  • Conclusion: Amifostine administered before and during the cisplatin infusion can significantly reduce the risk of severe ototoxicity in patients with AR medulloblastoma receiving dose-intense chemotherapy. (elsevier.com)
  • Amifostine was administered at a dose of 740 mg/m2 before chemotherapy . (bvsalud.org)
  • In these people, amifostine can help reduce harmful effects of chemotherapy on the kidneys. (chemocare.com)
  • Amifostine is given into a vein (intravenous, IV) infusion starting about 15-30 minutes before chemotherapy or radiation therapy is scheduled to begin. (chemocare.com)
  • We are also looking at the effects of heating the chemotherapy to a temperature of 42 degrees Celsius and the effect of cytoprotection agents: amifostine and sodium thiosulfate to counteract potential side effects of chemotherapy. (asbestosismesothelioma.com)
  • Amifostine, which is used in cancer chemotherapy. (wikipedia.org)
  • Listing your company for AMIFOSTINE TRIHYDRATE allows buyers to find your information through our directory pages which appear in the top positions when a search is conducted in Google, Yahoo! (poulvet.com)
  • Category API Standards CAS Number 112901-68-5 Molecular Weight 268.27 Molecular Formula C5H21N2O6PS Application Notes Amifostine Trihydrate is a widely used cytoprotective and radio-protective agent. (srgroupchemical.com)
  • Novel method of manufacture of high purity Amifostine trihydrate. (srgroupchemical.com)
  • The study investigators concluded, based on their observations and objective measurements, that subcutaneous amifostine may postpone the onset of acute esophagitis in a subset of patients with small cell lung carcinoma receiving concurrent chemoradiotherapy. (prnewswire.com)
  • Subcutaneous (SbQ) Versus Intravenous (IV) Administration of Amifostine for Head and Neck (HN) Cancer Patients Receiving Radiotherapy (RT): Prelimi. (oncolink.org)
  • Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. (curehunter.com)
  • Although intravenous administration is the standard route, pharmacokinetic studies have shown acceptable plasma levels of the active metabolite of amifostine (WR-1605) after subcutaneous administration. (curehunter.com)
  • The subcutaneous amifostine regimen was well tolerated by 85% of patients. (curehunter.com)
  • To assess the tolerance to subcutaneous amifostine and its effect on saliva production. (druglib.com)
  • The aim of this study was to assess the efficacy of subcutaneous amifostine in preventing radiation colitis in patients irradiated for pelvic neoplasms, by combining clinical, endoscopic and histopathologic data. (biomedcentral.com)
  • p53 protein regulates the effects of amifostine on apoptosis, cell cycle progression, and cytoprotection. (nih.gov)
  • These findings indicate that amifostine-induced G1 arrest and cytoprotection are mediated via a pathway that is dependent on p53 protein and that amifostine-induced expression of p21 protein is not sufficient to sustain a G1 arrest or to mediate cytoprotection. (nih.gov)
  • Amifostine is also used to decrease dryness in the mouth caused by radiation treatment after surgery for head and neck cancer. (medlineplus.gov)
  • When amifostine is used to reduce the severe dry mouth caused by radiation treatment, it is usually given over 3 minutes starting 15-30 minutes before your radiation treatment. (medlineplus.gov)
  • Amifostine is also used to prevent severe dry mouth caused by radiation treatment of the head and neck, which can affect the salivary gland. (cigna.com)
  • The recommended dose of amifostine is 200 mg/m2 administered once daily as a 3 minute intravenous infusion, starting 15 to 30 minutes prior to standard fraction radiation therapy (1.8-2.0 Gy). (drugs.com)
  • Amifostine is a drug that is used to treat moderate to severe xerostomia (dry mouth) for those who receive radiation therapy for head and neck cancer. (clinicaltrials.gov)
  • This study will examine the effectiveness of adding Amifostine in the hopes of reducing the side effects of radiation. (clinicaltrials.gov)
  • Patients were randomized to either 340 mg/m² IV amifostine, given daily 15 to 20 minutes before radiation, followed by radiation at 2 Gy/day, 5 days per week, to a total dose of 55 to 60 Gy, or to the same regimen without amifostine. (cancernetwork.com)
  • In the study described herein, the chelating complex micelles (CCM) composed of ferrous ion, poly(ethylene glycol)- block -poly (glutamic acid) (PEG-b-PGA), and cytoprotectant amifostine (WR-2721) are designed for the prevention of radiation damage. (omicsonline.org)
  • The clinically approved cytoprotector amifostine, designated WR-2721, [S-2-(3-aminopropylamino)ethylphosphorothioic acid], protects against both radiation and drug-induced mutagenesis in animal systems. (oup.com)
  • Mell LK, Movsas B. Pharmacologic normal tissue protection in clinical radiation oncology: focus on amifostine . (ethyol.com)
  • Amifostine is used to help prevent or lessen some of the side effects on the kidneys and salivary glands that are caused by cisplatin (a cancer medicine) or radiation therapy. (explainingmedicine.com)
  • Amifostine is a cytoprotective drug which is used for minimizing the side effects of radiation treatment as well as certain chemotherapic agents. (chemistrylearner.com)
  • Amifostine is also administered to patients undergoing radiation treatment for head and neck cancer to relieve the symptoms of xerostomia or dryness of mouth. (chemistrylearner.com)
  • In this study, we aimed to compare the protective effects of melatonin and amifostine on radiation-induced oxidative stress. (comu.edu.tr)
  • Amifostine can help relieve dry mouth problems for patients with head and neck cancer who are undergoing radiation treatment. (chemocare.com)
  • Five Patients, who were admitted to the department of radiation oncology, Inselspital Bern with histopathologically characterized unilateral malignant tumors of the orbital region and who gave informed consent for treatment with RT or CT-RT combined with amifostine, where included in this study. (springer.com)
  • This study aimed to investigate the efficacy of prophylactic amifostine in reducing the risk of severe radiation colitis in cancer patients receiving radical radiotherapy to the pelvis. (biomedcentral.com)
  • Amifostine given subcutaneously can lower the risk of acute severe radiation colitis in patients who receive radical radiotherapy to pelvic tumors. (biomedcentral.com)
  • Amifostine is an organic thiophosphate prodrug which is hydrolysed in vivo by alkaline phosphatase to the active cytoprotective thiol metabolite, WR-1065. (wikipedia.org)
  • Amifostine is a thiophosphate cytoprotective agent developed as a radio protector [ 11 ]. (omicsonline.org)
  • Amifostine can be described as an organic thiophosphate prodrug. (chemistrylearner.com)
  • Arm II (closed to accrual as of 11-25-03): Patients receive treatment as in arm I with the addition of amifostine IV over 15 minutes prior to cisplatin on day 1. (clinicaltrials.gov)
  • The addition of amifostine does not allow dose escalation of idarubicin when combined with high-dose ara-C. (elsevier.com)
  • The addition of amifostine to RT/CT-RT of patients with tumors localized in orbital region was found to be associated with absence of dry eye syndrome. (springer.com)
  • Amifostine (WR-2721) is an important cytoprotective agent. (curehunter.com)
  • Amifostine is a cytoprotective agent which scavenges the free radicals. (gazi.edu.tr)
  • Its aim was to determine if the amifostine group experienced less weight loss, less use of opiates during treatment, and/or allowed for a higher dose of radiotherapy to be delivered before opioids were needed for symptomatic relief of acute esophagitis. (prnewswire.com)
  • After week 3 we observed a significant reduction in acute esophagitis in patients who received amifostine,' Dr. Antonadou said. (cancernetwork.com)
  • Since there is enhanced production of reactive oxygen metabolites in glycerol-induced acute renal failure, we wanted to examine whether amifostine has a protective role against vascular reactivity and histological changes in kidneys isolated from glycerol-pretreated rabbits. (gazi.edu.tr)
  • Amifostine is effective in reducing the incidence and severity of acute mucositis , acute and late xerostomia in head and neck cancer patients . (bvsalud.org)
  • Amifostine is a cytoprotective compound that has been shown to protect against the acute cytotoxicities of anthracyclines in animal models. (elsevier.com)
  • In this study, we have investigated the in vivo effects of IL-4, IL-10, and amifostine on cytokine production in patients with acute myelogenous leukemia (AML). (elsevier.com)
  • Amifostine treated patients were less likely to develop histologically detectable mucosal lesions, which indicate protection from acute mucosal injury. (biomedcentral.com)
  • Amifostine is also indicated to reduce the incidence of xerostomia in patients undergoing radiotherapy for head and neck cancer. (wikipedia.org)
  • Common side effects of amifostine include nausea, vomiting, and low blood pressure. (rxwiki.com)
  • It evaluated the impact of amifostine on reducing GI toxicities among multiple myeloma patients undergoing transplant. (prnewswire.com)
  • The study, led by Ariel E Pollock M.D, Icahn School of Medicine at Mt. Sinai, New York , evaluated the impact of amifostine on protecting the esophagus. (prnewswire.com)
  • Patients receive intravenous amifostine over 10 minutes on day 0, followed by intravenous cyclophosphamide and carboplatin consecutively over 5-15 minutes. (knowcancer.com)
  • However, approximately 90% of the amifostine was rapidly cleared from plasma after 6 minutes after intravenous administration [ 13 ]. (omicsonline.org)
  • Thirty papers were reviewed for evidence on amifostine as an intervention for oral mucositis. (nih.gov)
  • Additional well-designed research is needed to clarify the role of amifostine as an intervention for oral mucositis. (nih.gov)
  • Furthermore, CCM-Ami pretreatment improved survival rates and median survival in C57BL/6 mice than did treatment with a corresponding dose of amifostine. (omicsonline.org)
  • Pretreatment with low dose of different combinations of DRDE-07, DRDE-30 and DRDE-35 with amifostine could recover biochemical alterations and histopathological changes caused by SM exposures. (who.int)
  • Amifostine was administered 15 minutes before the infusions of cisplatin and carboplatin in a total of 193 infusions. (unifesp.br)
  • Alberts, DS 1999, ' Protection by amifostine of cyclophosphamide-induced myelosuppression ', Seminars in Oncology , vol. 26, no. 2 SUPPL. (elsevier.com)
  • Comparison of uroprotective efficacy of mesna and amifostine in Cyclophosphamide- induced hemorrhagic cystitis in rats. (bvsalud.org)
  • This study demonstrated the efficacy of amifostine in prevention of cyclophosphamide-induced hemorrhagic cystitis. (bvsalud.org)
  • An exposure of cells to 40 microM of the disulfide form of amifostine was the most effective in repressing c-myc, i.e. 27% of control level. (oup.com)
  • amifostine is a topic covered in the Davis's Drug Guide . (drugguide.com)
  • In this study, we aimed to investigate the role of amifostine in the protection of CYP-induced HC and compare its efficacy with mesna. (bvsalud.org)
  • To test whether there is any effect of amifostine on event-free survival by comparing outcome of those treated with amifostine to those treated without on this study and with historic controls. (clinicaltrials.gov)
  • The amount of amifostine that you will receive depends on many factors, including your height and weight, your general health or other health problems, and the type of cancer or condition being treated. (chemocare.com)
  • 1. A pharmaceutical composition comprising a therapeutically effective amount of amifostine and sodium deoxycholate. (google.es)
  • 2. The pharmaceutical composition of claim 1 , wherein the amount of amifostine is from about 10 mg to about 3000 mg. (google.es)
  • 23. A pharmaceutical composition which comprises a therapeutically effective amount of amifostine, an amount of sodium deoxycholate, an amount of sorbitol and an amount of EDTA. (google.es)
  • The aim of the present study was to evaluate antioxidative ability of amifostine in blood serum of rats exposed to cyclophosphamide during two weeks after drug administration. (pjoes.com)
  • Our studies suggest that 2-CdA used together with amifostine is more toxic to leukemic CFU-GM than to their normal counterparts. (edu.pl)
  • It is recommended that antiemetic medication, including dexamethasone 20 mg intravenously and a serotonin 5-HT3 receptor antagonist, be administered prior to and in conjunction with amifostine. (drugs.com)
  • It is recommended that antiemetic medication be administered prior to and in conjunction with amifostine. (drugs.com)
  • Anti-nausea medicine may be given in conjunction with amifostine. (chemocare.com)
  • The amount or dosage of Amifostine received by the patient depends on several factors such as the height and weight of the patient, the general health profile as well as the health condition that is being treated. (chemistrylearner.com)
  • You should not breast-feed during your treatment with amifostine. (medlineplus.gov)
  • This research study is studying a drug called Amifostine as a treatment for squamous cell carcinoma in the head and/or neck area. (clinicaltrials.gov)
  • During my rads treatment I took two shots before they zapped my head called amifostine. (cancer.org)
  • The aim of this study was to review the available literature from 1966 until December 31, 2010 and define clinical practice guidelines for the use of amifostine for the prevention and treatment of oral mucositis in cancer patients. (nih.gov)
  • The body of evidence for the use of amifostine, in each cancer treatment setting was assigned an evidence level. (nih.gov)
  • No guideline was possible for amifostine in any cancer treatment setting due to inadequate and conflicting evidence. (nih.gov)
  • Review of the amifostine studies for the prevention and treatment of oral mucositis has found insufficient evidence to support its use in any cancer treatment setting for this purpose. (nih.gov)
  • In 32 patients (group 1), amifostine was delivered prior to the second daily radiotherapy treatment. (prnewswire.com)
  • This was to address the concern that amifostine might compromise the efficacy of the treatment,' Dr. Antonadou said. (cancernetwork.com)
  • There was no evidence of compromised treatment efficacy, and we concluded that daily doses of amifostine are well tolerated. (cancernetwork.com)
  • Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. (wiley.com)
  • In addition, treatment of HCT116 cells with amifostine alone resulted in apoptotic cell death. (nih.gov)
  • The side effects of Amifostine are reversible in most cases and will heal completely after completion of treatment. (chemistrylearner.com)
  • In a pivotal phase III study of cisplatin/cyclophosphamide with or without amifostine, amifostine treatment reduced course-by-course cumulative bone marrow damage when compared with the course-by-course cumulative myelosuppression experienced by those treated with cisplatin/cyclophosphamide alone. (elsevier.com)
  • Patients and Methods: The primary objective was to determine whether, in patients with AR medulloblastoma (n = 62), amifostine would decrease the need for hearing aids (defined as ≥ grade 3 ototoxicity in one ear) compared with a control group (n = 35), 1 year from initiating treatment. (elsevier.com)
  • Before starting amifostine treatment, make sure you tell your doctor about any other medications you are taking (including over-the-counter drugs, vitamins, or herbal remedies). (chemocare.com)
  • Your blood pressure medication will likely be stopped for 24 hours before treatment with amifostine. (chemocare.com)
  • 95% CI, 0.31-2.54).Although patients in this study were not randomly assigned to amifostine treatment, we found evidence in favor of amifostine administration for protection against cisplatin-induced serious hearing loss in average-risk but not in high-risk, medulloblastoma patients. (duke.edu)
  • It is noteworthy to understand the medicines prescribed for the treatment of Amifostine Hydrate Market needs to be accurately dispensed by the hospital pharmacist to avoid occurrence of any drug related adverse events. (picayunecurrent.com)
  • Sodium azide and an active metabolite of amifostine (WR1065) increase cell viability in simultaneous treatment with cisplatin. (springer.com)
  • Amifostine may prevent gastro-intestinal toxicities in certain cancer patients. (prnewswire.com)
  • Additional data have shown that amifostine-mediated tumor protection, in any clinical scenario, is unlikely. (wikipedia.org)
  • Hospitals & clinics are spearheading the end-user segment for the Amifostine Hydrate market. (curiousdesk.com)
  • North America is presently holding the largest market share in the geography segment for the Amifostine Hydrate market . (curiousdesk.com)
  • North America is spearheading the segment for the Amifostine Hydrate Market. (picayunecurrent.com)
  • Hospital pharmacy is presently leading the distribution channel segment for Amifostine Hydrate Market. (picayunecurrent.com)
  • Europe is in the 2nd place in the regional segment for the Amifostine Hydrate Market. (picayunecurrent.com)
  • Supportive regulatory environment provided by the European Medical Agency (EMA), for the sale and distribution of Amifostine Hydrate Market together accentuate the market growth in the region. (picayunecurrent.com)
  • Additionally, the strategic collaboration between the pharmaceutical companies and academic research institutes for the development of Amifostine Hydrate Market further propel the market growth in the region. (picayunecurrent.com)
  • Asia Pacific is anticipated to be the fastest-growing segment Amifostine Hydrate Market during the forecast period. (picayunecurrent.com)
  • Developing healthcare infrastructure and flourishing generic drugs market determine the market growth of Amifostine Hydrate Market in the Asia Pacific region. (picayunecurrent.com)
  • Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer. (bvsalud.org)
  • Sixty-seven head and neck cancer patients were randomized to receive radiotherapy or radiotherapy plus Amifostine . (bvsalud.org)
  • Patients with pelvic tumours referred for radical radiotherapy who consented participation in this trial, were randomly assigned to receive daily amifostine (A) (subcutaneously, 500 mg flat dose) before radiotherapy or radiotherapy alone (R). Sigmoidoscopy and blinded biopsies were scheduled to conduct prior to initiation and following completion of radiotherapy and again 6 to 9 months later. (biomedcentral.com)
  • Netherlands - PMID 16804929 - "Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. (wikibooks.org)
  • Inside cells, amifostine detoxifies reactive metabolites of platinum and alkylating agents, as well as scavenges free radicals. (wikipedia.org)
  • Healthy cells are preferentially protected because amifostine and metabolites are present in healthy cells at 100-fold greater concentrations than in tumour cells. (drugbank.ca)
  • WR-33278, metabolites of amifostine on gene expression in CHO-AA8 cells. (oup.com)
  • It is probably connected with low concentrations of amifostine active metabolites in the serum. (pjoes.com)
  • Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma. (duke.edu)
  • The purpose of this study was to evaluate amifostine for protection from cisplatin-induced serious hearing loss in patients with average-risk medulloblastoma by extending a previous analysis to a much larger sample size. (duke.edu)
  • Amifostine as a thiol compound possesses antioxidant properties and protects only healthy cells against damage, mainly by scavenging reactivity oxygen species, competing with oxygen to prevent oxygen radical interactions with DNA, and promoting cell repair through hydrogen donation to reactive oxygen species. (pjoes.com)
  • N-acetyl cysteine protects against DNA damage, suggested to be comparable to amifostine. (wikipedia.org)
  • Amifostine is only found in individuals that have used or taken this drug. (hmdb.ca)
  • www.drugguide.com/ddo/view/Davis-Drug-Guide/51036/all/amifostine. (drugguide.com)
  • Medicine Central , im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/51036/all/amifostine. (unboundmedicine.com)
  • Along with Amifostine, anti-nausea drug may also be administered to the patient. (chemistrylearner.com)
  • There are certain general side effects of the Amifostine drug. (chemistrylearner.com)
  • You may be given other medications to prevent nausea or vomiting while you are receiving amifostine. (cigna.com)
  • Fifty female Wistar rats (3-4 months old, weighing 200 +/- 25 g) were divided into five groups (with ten rats each) and treated as follows: control (Cont), radiotherapy alone (RT), radiotherapy + amifostine (RT+A-MI), radiotherapy + melatonin (RT+MEL), radiotherapy + amifostine + melatonin (RT+AMI+MEL). (comu.edu.tr)
  • Amifostine comes as a powder to be mixed with liquid to be injected intravenously (into a vein) by a doctor or nurse in a medical facility. (medlineplus.gov)
  • Amifostine can be administered intravenously or subcutaneously after reconstitution with normal saline. (wikipedia.org)
  • Patients received bleomycin 15 IU/m 2 on Day 1, then etoposide 100 mg/m 2 per day, amifostine 825 mg/m 2 per day, and cisplatin 40 mg/m 2 per day on Days 1-5, intravenously. (elsevier.com)
  • Amifostine 740 mg was administered at 24 hours and 15 min before high-dose melphalan. (prnewswire.com)
  • We report the results of a phase I study of dose escalation of idarubicin with amifostine and high-dose ara-C in patients with relapsed or refractory AML or myelodysplastic syndrome (MDS). (elsevier.com)
  • Amifostine is rapidly dephosphorylated by alkaline phosphatase in tissues primarily to the active free thiol metabolite and, subsequently, to a less active disulfide metabolite. (drugbank.ca)
  • Amifostine is used to protect the kidneys from harmful effects caused by cisplatin when given to patients with ovarian cancer. (cigna.com)
  • Here you can see the latest Amifostine In Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, Or Endometrial Cancer articles that have been published worldwide. (bioportfolio.com)
  • In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Amifostine In Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, Or Endometrial Cancer Companies in our database. (bioportfolio.com)
  • You can also find out about relevant Amifostine In Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, Or Endometrial Cancer Drugs and Medications on this site too. (bioportfolio.com)
  • Amifostine is prescribed for women having advanced ovarian cancer and receiving frequent doses of cisplatin. (chemistrylearner.com)
  • Do not receive it if you had an allergic reaction to amifostine. (explainingmedicine.com)
  • Amifostine may be inadvisable if you have had a hypersensitivity (allergic) reaction to aminothiol compounds or mannitol. (chemocare.com)
  • Systematic review of amifostine for the management of oral mucositis in cancer patients. (nih.gov)
  • Amifostine may also be used for purposes not listed in this medication guide. (cigna.com)
  • You will need to stop taking any blood pressure medication for at least 24 hours before you are treated with amifostine. (cigna.com)
  • To be sure this medication is not causing harmful effects, your blood pressure will be watched closely while you are receiving amifostine. (cigna.com)